The symposium was an excellent opportunity for the expertise to exchange their clinical experience together and with our eminent speakers. It was very interactive and the discussion was highly scientific.
Minapharm Pharmaceuticals receives regulatory approval from the Paul-Ehrlich Institute for a phase 1 multi-center clinical trial in Germany for its Adalimumab biosimilar
Bioventure, Minapharm Pharmaceuticals and MiGenTra Sign an Exclusive Agreement
for the Commercialization of Multiple Biosimilar Candidates of Alvotech
in the Middle East and Africa
As a global leader in biotechnology & cellular engineering, ProBioGen-Minapharm
As a continuation of Minapharm unique series of "Expert Panel",
The meeting was chaired by Prof. Abdel-Shakour EL MOHAMADY.
The First Netilmicin The Least Resistance
The First Netilmicin Combination the Quick Relief for Ocular Inflammation
Striking Glaucoma Treatment Goals Balancing EFFICACY, COMPLIANCE & AFFORADABILITY
Robust & long lasting correction of serum vitamin D levels For prophylaxis and/or treatment of vitamin D deficiency
Stay connected, subscribe to our newsletter for news and updates.